Advertisement

Diabetic macular edema: 4 answers about anti-VEGF therapy

Anti-VEGF therapy can help protect your vision and even prevent blindness.

One of the mainstays of treatment for DME are injections of anti-VEGF medications.

Updated on April 9, 2025

Diabetic macular edema (DME) is one of several eye conditions that can occur when a person has diabetes.

DME is caused by fluid leaking out of blood vessels inside the eye. These fluids and substances accumulate inside the macula, a cluster of light-sensitive cells located in the back of the eyeball. The buildup causes the macula to swell.

When the macula becomes swollen, vision problems occur. Vision can become blurred or wavy, floaters can appear, and colors can seem dulled. DME can lead to blindness, especially when left untreated.

One of the mainstays of treatment for DME is injections of anti-VEGF drugs.

What is anti-VEGF?

VEGF stands for vascular endothelial growth factor. This is a signaling protein that is made and released in the body. It helps stimulate the growth of new blood vessels. 

DME typically occurs alongside another form of diabetic eye disease called diabetic retinopathy. They happen when diabetes damages the blood vessels inside the retina, causing them to leak and to become blocked. 

The body tries to compensate by creating new blood vessels, and releases VEGF inside the eye. However, high amounts of VEGF contribute to the weakening and breakdown of blood vessels in the retina, causing them to leak. In advanced stages of diabetic eye disease, new blood vessels will form, a process called neovascularization. These new blood vessels will not work well and will also leak fluid into the eye. 

Diabetic macular edema can happen at any stage of this process. Blocking VEGF helps stop blood vessels from leaking fluid into the eye. This allows the body to clear out the excess fluid in the macula and the swelling to ease.

Will anti-VEGF improve my vision?

When it comes to DME and other forms of diabetic eye disease, every person is different. A primary treatment goal is preventing DME from getting worse. Left untreated, DME will progress and eventually cause serious vision impairment or blindness.

Anti-VEGF drugs will help prevent these outcomes. Many people with DME who receive anti-VEGF therapy also see improvement in their vision. Your healthcare providers will be better able to explain what results you can expect.

What do I need to know about anti-VEGF injections?

Anti-VEGF therapy needs to be delivered directly into the eyeball with an injection, which can be intimidating. Here’s what you need to know:

  • The needle used for anti-VEGF injections is very, very thin.
  • A numbing agent is applied to the eye is numbed before the injection to help minimize any discomfort.
  • The injection is typically painless. Most people describe feeling pressure against the eyeball, but not pain.
  • The eye is washed before and after the injection.
  • The procedure is done in your ophthalmologist’s office. The injection takes just a few seconds, though the appointment will be about 15 minutes.

There are several different anti-VEGF drugs available. They work differently to block VEGF in the eye and require different dosing schedules. Your ophthalmologist will advise you on your drug options and your treatment schedule.

How do I get the most out of treatment?

Anti-VEGF therapy isn’t the only treatment option for DME. Corticosteroids can also be used to reduce inflammation, and a type of laser surgery called photocoagulation can be used to close off leaking blood vessels.

Regardless of what treatment options you and your healthcare provider decide on, good diabetes management will help you get the best possible result from treatment. Controlling blood glucose levels, blood pressure, and cholesterol helps prevent further damage to the eyes, and will be an essential part of every treatment plan for DME and other forms of diabetic eye disease.

Article sources open article sources

MedlinePlus. Diabetic Eye Problems. November 13, 2024.
Mayo Clinic. Diabetic macular edema. Accessed April 9, 2025.
PreventBlindness.org. Diabetes-Related Macular Edema. Accessed April 9, 2025.
National Eye Institute. Macular Edema. November 29, 2024.
The Foundation of the American Society of Retina Specialists. Macular Edema. Accessed April 9, 2025.
Merck Manual Consumer Version. Diabetic Retinopathy. April 2024.
Daniel Porter. What Is Macular Edema? American Academy of Ophthalmology. March 16, 2022. September 23, 2024.
David Turbert. Anti-VEGF Treatments. American Academy of Ophthalmology. July 26, 2023.
MedlinePlus. Diabetes and eye disease. February 10, 2023.
Kuroiwa DAK, Malerbi FK, Regatieri CVS. New Insights in Resistant Diabetic Macular Edema. Ophthalmologica. 2021;244(6):485-494.
Kierstan Boyd. Diabetic Retinopathy: Causes, Symptoms, Treatment. American Academy of Ophthalmology. October 11, 2024.
Cleveland Clinic. Neovascularization of The Eye. September 7, 2022.
American Optometric Association. Diabetic retinopathy. Accessed April 9, 2025.
American Academy of Ophthalmology. Diabetic Macular Edema. December 12, 2024.
National Institute of Diabetes and Digestive and Kidney Diseases. Diabetic Eye Disease. May 2017.

Featured Content

article

Finding support when living with diabetic macular edema

Having a good support system can help you meet the challenges of living with vision loss from DME.
article

3 ways to prevent diabetic eye disease from getting worse

Learn how careful diabetes management helps keep your eyes as healthy as possible.
article

Diabetic macular edema: what to expect from anti-VEGF injections

What you can expect at an appointment for anti-VEGF therapy injections to treat diabetic macular edema.